Beta-2 chimaerin (CHN2)

Beta-2 chimaerin is a signaling protein that functions as a Rac-specific GTPase-activating protein (GAP), playing a pivotal role in regulating the actin cytoskeleton and cell motility [UniProt P52757]. It is characterized by a unique domain structure including an N-terminal SH2 domain, a central C1 domain that binds diacylglycerol (DAG), and a C-terminal GAP domain [PubMed: 11022048]. The binding of DAG or synthetic analogs like phorbol esters to the C1 domain triggers the translocation of Beta-2 chimaerin to the plasma membrane, where it inactivates Rac1 by accelerating GTP hydrolysis [PubMed: 17210646]. In many clinical contexts, particularly oncology, Beta-2 chimaerin is recognized as a tumor suppressor; its expression is frequently reduced in high-grade tumors, leading to uncontrolled Rac1 activation and enhanced metastasis [PubMed: 20647451]. Beyond cancer, it is involved in T-cell receptor signaling and the fine-tuning of neuronal morphology [PubMed: 18258919]. Pharmacological targeting of Beta-2 chimaerin often involves small molecules like bryostatins that mimic DAG, aiming to restore GAP activity and suppress aberrant Rac1 signaling in disease states [PubMed: 25605724]. Its role as a non-kinase phorbol ester receptor makes it a distinct target from the more common Protein Kinase C family [NCBI Gene: 1124].

Other names

Beta-chimaerinRho GTPase-activating protein 3CHN2BCHNARHGAP3Beta2-chimaerin

Activation of GTPase-activating protein (GAP) activity through C1 domain binding, leading to the inactivation of Rac1 GTPase.